Literature DB >> 14610242

Potentiation of carbon tetrachloride hepatotoxicity and lethality in type 2 diabetic rats.

Sharmilee P Sawant1, Ankur V Dnyanmote, Kartik Shankar, Pallavi B Limaye, John R Latendresse, Harihara M Mehendale.   

Abstract

There is a need for well characterized and economical type 2 diabetic model that mimics the human disease. We have developed a type 2 diabetes rat model that closely resembles the diabetic patients and takes only 24 days to develop robust diabetes. Nonlethal doses of allyl alcohol (35 mg/kg i.p.), CCl(4) (2 ml/kg i.p.), or thioacetamide (300 mg/kg i.p.) yielded 80 to 100% mortality in diabetic rats. The objective of the present study was to investigate two hypotheses: higher CCl(4) bioactivation and/or inhibited compensatory tissue repair were the underlying mechanisms for increased CCl(4) hepatotoxicity in diabetic rats. Diabetes was induced by feeding high fat diet followed by a single dose of streptozotocin on day 14 (45 mg/kg i.p.) and was confirmed on day 24 by hyperglycemia, normoinsulinemia, and oral glucose intolerance. Time course studies (0-96 h) of CCl(4) (2 ml/kg i.p.) indicated that although initial liver injury was the same in nondiabetic and diabetic rats, it progressed only in the latter, culminating in hepatic failure, and death. Hepatomicrosomal CYP2E1 protein and activity, lipid peroxidation, glutathione, and (14)CCl(4) covalent binding to liver tissue were the same in both groups, suggesting that higher bioactivation-based injury is not the mechanism. Inhibited tissue repair resulted in progression of injury and death in diabetic rats, whereas in the nondiabetic rats robust tissue repair resulted in regression of injury and survival after CCl(4) administration. These studies show high sensitivity of type 2 diabetes to model hepatotoxicants and suggest that CCl(4) hepatotoxicity is potentiated due to inhibited tissue repair.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610242     DOI: 10.1124/jpet.103.058834

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Hepatocyte-specific ablation of spermine/spermidine-N1-acetyltransferase gene reduces the severity of CCl4-induced acute liver injury.

Authors:  Kamyar Zahedi; Sharon L Barone; Jie Xu; Nora Steinbergs; Rebecca Schuster; Alex B Lentsch; Hassane Amlal; Jiang Wang; Robert A Casero; Manoocher Soleimani
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-21       Impact factor: 4.052

2.  Biological Evaluation of Polyherbal Ayurvedic Cardiotonic Preparation "Mahamrutyunjaya rasa".

Authors:  Pallavi D Rai; Sadhana J Rajput
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-02       Impact factor: 2.629

3.  Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice.

Authors:  Claudia Mitchell; Marie-Anne Robin; Alicia Mayeuf; Meriem Mahrouf-Yorgov; Abdellah Mansouri; Marie Hamard; Dominique Couton; Bernard Fromenty; Hélène Gilgenkrantz
Journal:  Am J Pathol       Date:  2009-10-01       Impact factor: 4.307

4.  The antioxidant activity of chondroitin-4-sulphate, in carbon tetrachloride-induced acute hepatitis in mice, involves NF-kappaB and caspase activation.

Authors:  G M Campo; A Avenoso; S Campo; G Nastasi; P Traina; A D'Ascola; C A Rugolo; A Calatroni
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

5.  Effects of rosiglitazone with insulin combination therapy on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.

Authors:  Servet Kavak; Lokman Ayaz; Mustafa Emre
Journal:  Exp Diabetes Res       Date:  2012-07-05

6.  Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches.

Authors:  Sudin Bhattacharya; Lisl K M Shoda; Qiang Zhang; Courtney G Woods; Brett A Howell; Scott Q Siler; Jeffrey L Woodhead; Yuching Yang; Patrick McMullen; Paul B Watkins; Melvin E Andersen
Journal:  Front Physiol       Date:  2012-12-14       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.